Table IV.
Factors associated with time to onset of physician-diagnosed recurrent wheezing by multivariable Cox proportional hazards regression for subgroups based on family history
| Hazard Ratio (95% CI) |
||||
|---|---|---|---|---|
| No history |
History |
|||
| Variable | vs combined untreated groups | vs untreated non-RSV hospitalized group | vs combined untreated groups | vs untreated non-RSV hospitalized group |
| Asthma | ||||
| Palivizumab treatment | 0.33 (1.51-0.74)† | 0.34 (0.15-0.79)∗ | NA | NA |
| Member of multiple birth | NA | NA | 11.09 (2.14,57.45)† | NA |
| Siblings in household | NA | NA | 0.27 (0.09-0.81)∗ | NA |
| Siblings in day care | NA | NA | 6.36 (1.76-22.99)† | 1.84 (1.10-3.09)∗ |
| Gestational age (per 1-wk increase) | 0.84 (0.73-0.96)† | 0.79 (0.67-0.92)† | NA | NA |
| Atopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies | ||||
| Palivizumab treatment | 0.21 (0.08-0.59)† | 0.20 (0.07-0.56)† | NA | NA |
| Family history of asthma | NA | NA | 3.77 (1.60-8.92)† | 2.94 (1.14-7.61)∗ |
| Gestational age (per 1-wk increase) | 0.82 (0.70-0.96)∗ | 0.80 (0.67-0.95)∗ | NA | 0.81 (0.66-0.98)∗ |
NA, not applicable, variable was not included in the final model.
∗
Statistically significant at the .050 level.
†
Statistically significant at the .010 level.